Please assess the completion status of the following clinical trial:

Trial Title: GORE PROPATEN Vascular Graft vs. Disadvantaged Autologous Vein Graft

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient requires below-knee bypass secondary to severe claudication, rest pain or tissue loss due to peripheral arterial occlusive disease.~2. Patient meets the disadvantaged autologous vein criteria described in Section 4.1.~3. Patient has a post-operative life expectancy greater than one year.~4. Patient is at least 21 years of age.~5. Patient is able to comply with all study requirements and be available for follow-up visits at 1, 6, 12, 24 and 36-months post-procedure.~6. Patient is willing and able to provide written, informed consent.~Exclusion Criteria:~1. Patient has had a previous instance of Heparin Induced Thrombocytopenia type 2 (HIT-2) or has known hypersensitivity to heparin.~2. Patient requires an infragenicular bypass for reasons other than peripheral arterial occlusive disease.~3. Patient requires sequential extremity revascularizations or other procedures that require use of additional vascular grafts.~4. Patient is in need of, or is scheduled for, a cardiac surgical procedure or a different vascular surgical procedure within 30 days of study procedure. However, inflow procedures that facilitate the bypass are permitted, as long as they are not performed at the same sitting as the bypass procedure.~5. Patient has been previously randomized for this study.~6. Patient has active infection in the region of graft placement.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GORE PROPATEN Vascular Graft: (Type: ACTIVE_COMPARATOR): None
- Disadvantaged Autologous Vein Graft (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).